Key Highlights
- 0.193% is the gap by which the 50-day average of USD 72.94 sits below the 200-day average of USD 73.08 for BridgeBio Pharma (NASDAQ:BBIO), per published market data (October 16, 2026 intraday). The price of USD 66.07 is 9.6% below the 200-day (own arithmetic).
- USD 222.4 million was Attruby net product revenue in the second quarter, against USD 71.5 million a year earlier, per management commentary on the August 10, 2026 report. Total revenue was USD 243.7 million, up 120% from USD 110.6 million.
- November 27, 2026 is the FDA decision date for BBP-418 in limb-girdle muscular dystrophy, under priority review. BridgeBio Pharma (NASDAQ:BBIO) also holds a February 4, 2027 date for infigratinib and May 8, 2027 for encaleret.
- USD 1 billion of preferred equity led by Sixth Street closed on July 1, 2026. Cash was USD 720.2 million at June 30, 2026, so pro forma liquidity was USD 1,720.2 million (own arithmetic), while BridgeBio Pharma (NASDAQ:BBIO) still reports an operating loss.
Price Action and Cross Mechanics
A death cross occurs when the 50-day simple average falls below the 200-day, and it lags because both average past closes. The USD 0.14 gap is own arithmetic. The price of USD 66.07 is 29.3% below the 52-week high of USD 93.42 and 25.2% above the low of USD 52.75 (own arithmetic), and the stock is down 12.67% year to date. No single October catalyst was identified. Structural pressures include the February 5, 2026 revocation of a Pfizer tafamidis patent in Europe, which sent shares down 15%, and a May 26 payer-risk downgrade from Raymond James.
Fundamentals and Financing
Attruby grew 23% in the quarter against 19% for the ATTR cardiomyopathy market, per management. The operating loss narrowed to USD 107.1 million from USD 134.3 million, while the company expects results to stay stable for several quarters before moving toward break-even. Third quarter consensus is revenue of USD 281.1 million, 15.3% above the second quarter (own arithmetic), with EPS of negative USD 0.57. The preferred equity extends runway, but conversion terms and dividends dilute common holders and were not reviewed.
Risks and Catalysts
Short interest is 11.73% of float with 5.85 days to cover per published market data, and the CEO sold USD 690,800 of stock on September 22, 2026. Tafamidis generic entry is modelled by Evercore ISI from December 2028, and Attruby has no head-to-head trial against it. UBS assumed coverage with a Buy rating and a USD 92 target, and Wells Fargo reaffirmed Buy on October 16. The next dated events are the report estimated for October 28, 2026 and the November 27 decision.
Where Things Stand
Yes, technically: BridgeBio Pharma (NASDAQ:BBIO) is in a death cross, but a USD 0.14 gap says less than the 9.6% distance below the 200-day average. Evidence is mixed. Revenue more than doubled in the second quarter and three FDA decisions are scheduled, yet the stock has lost 29.3% from its high, losses persist, and payer and generic risk weigh on the multiple. A binary event sits on November 27, 2026, when BBP-418 receives its FDA decision. Reversal needs closes well above the USD 72.94 average, and the crossover is not a forecast.






Please wait processing your request...